Contact Us

News

November 18, 2024

Antharis Therapeutics Appoints Patric Nelson as Chief Business Officer

November 7, 2024

Antharis Therapeutics CEO, Dr. Raphael Ribeiro-Pinaud, Featured in Biotech Leader Spotlight Series

October 15, 2024

Antharis Therapeutics Welcomes Daniel Yazbeck as Head of Corporate Strategy

March 18, 2024

Antharis Therapeutics CEO Dr. Raphael Ribeiro-Pinaud Named Among “Most Impactful CEOs of the Year 2024" by CIO Today

February 19, 2024

Antharis Therapeutics Awarded “Biopharmaceutical Company of the Year 2024 - California” by Global Health and Pharma

February 10, 2024

Antharis Therapeutics Recognized as a Leading Emerging Biopharmaceutical Company

January 15, 2024

Antharis Therapeutics CEO, Dr. Raphael Ribeiro-Pinaud, Named “Most Inpiring Business Leader of 2024” by CXO Outlook for Pioneering Advances in Biopharma Innovation

December 18, 2023

Antharis Therapeutics Selected as a Top 10 Biotech Startup in 2023 by Pharma Tech Outlook for Pioneering Immuno-Oncological Cancer Treatments

August 23, 2023

Antharis Therapeutics Acquires Galileo Biotech, including Its GMP-Certified Development and Manufacturing Facility

July 14, 2022

Antharis Therapeutics Acquires Cassyni Biopharma and Its Portfolio of Assets

July 14, 2022

Antharis Therapeutics Announces Successful Completion of Its Series A Financing Round

(21) 3576-3513
Av. das Américas, 12900 - B1, Loja SS 115 - Barra da Tijuca
Rio de Janeiro/RJ, Brazil (22790-702)
Linkedin
contato@galileobio.com

PRIVACY POLICY & TERMS OF USE

Copyright © 2024 Galileo Biotech develops cutting-edge therapies that harness the immune system towards cures for a number of unmet medical needs, including a variety of cancers.